More Robert J's Form 4 filing
Tyra Biosciences, Inc. (TYRA) · filed Nov 25, 2025
- Accession no.
- 0001193125-25-297551
- Filed
- Nov 25, 2025
- Trade date
- Nov 21, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $5.00M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| More Robert JCIK 0001207792 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | Common Stock | SSaleDisposed | −246,871 | $20.25F2 | −$4,999,137.75 | 3,833,425 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.25 to $21.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.